AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health (NIH).
AgeneBio, a Baltimore-based biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of Health.
“What this could mean for thousands of patients is they may never cross over into full-blown Alzheimer’s dementia,” said Jerry McLaughlin, CEO of AgeneBio, the Baltimore company founded by a Hopkins researcher who discovered that the drug might…
Johns Hopkins University researchers have received an estimated $7.5 million NIH grant to test treatment to prevent or delay dementia.
What could be one of the first treatments to delay or prevent Alzheimer’s disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the drug being developed by a Baltimore start-up and the Johns Hopkins University.
Public-private partnership will support first and only trial to reduce hippocampal overactivity during aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD, September 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, announced today that its HOPE4MCI Phase 3 clinical trial has received support from the National Institutes of…